Review
Published on 09 Jan 2023
Radiometal chelators for infection diagnostics
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.1058388
- 5,446 views
- 8 citations
Type at least 3 characters
23 articles
Articles
Original Research
Published on 22 Jul 2022
ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.934446
- 1,498 views
Perspective
Published on 03 May 2022
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.863101
- 3,909 views
- 5 citations
Case Report
Published on 15 Mar 2022
Anti-thyroglobulin Antibodies as a Possible Risk Factor for Graves' Disease After Radioiodine Treatment for Toxic Nodular Goiter: Case Report
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2022.858062
- 2,054 views
- 1 citation
Review
Published on 01 Feb 2022
Imaging Lymphoma With F-18 Fluorodeoxyglucose PET-CT: What Should Be Known About Normal Variants, Pitfalls, and Artifacts?
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2021.826046
- 6,669 views
Review
Published on 21 Jan 2022
Shared Decision Making for Radioiodine Therapy and the Actual Pattern of Care in Intermediate-Risk Differentiated Thyroid Carcinoma
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2021.797522
- 1,628 views
- 1 citation
Original Research
Published on 30 Nov 2021
Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence
in Radionuclide Therapy
Frontiers in Nuclear Medicine
doi 10.3389/fnume.2021.785768
- 1,694 views
- 2 citations